We assign a fundamental rating of 4 out of 10 to NTRA. NTRA was compared to 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for NTRA as it has an excellent financial health rating, but there are worries on the profitability. NTRA is valued quite expensively, but it does show have an excellent growth rating.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

NTRA had negative earnings in the past year.
In the past year NTRA had a positive cash flow from operations.
NTRA had negative earnings in each of the past 5 years.
NTRA had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

The Return On Assets of NTRA (-16.97%) is better than 78.10% of its industry peers.
With a decent Return On Equity value of -24.69%, NTRA is doing good in the industry, outperforming 80.00% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-16.97%
ROE	-24.69%
ROIC	N/A

ROA(3y)-26.97%

ROA(5y)-28.74%

ROE(3y)-50.12%

ROE(5y)-53.96%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

NTRA has a better Gross Margin (63.66%) than 79.43% of its industry peers.
NTRA's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for NTRA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	63.66%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y7.09%

GM growth 5Y7.51%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
NTRA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NTRA has been increased compared to 5 years ago.
The debt/assets ratio for NTRA has been reduced compared to a year ago.

2.2 Solvency

NTRA has an Altman-Z score of 34.16. This indicates that NTRA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of NTRA (34.16) is better than 93.71% of its industry peers.
NTRA has a debt to FCF ratio of 0.86. This is a very positive value and a sign of high solvency as it would only need 0.86 years to pay back of all of its debts.
NTRA has a better Debt to FCF ratio (0.86) than 94.10% of its industry peers.
A Debt/Equity ratio of 0.06 indicates that NTRA is not too dependend on debt financing.
NTRA has a Debt to Equity ratio of 0.06. This is in the lower half of the industry: NTRA underperforms 60.38% of its industry peers.
Although NTRA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.

		Industry Rank	Sector Rank
Debt/Equity	0.06
Debt/FCF	0.86
Altman-Z	34.16

ROIC/WACCN/A

WACC8.84%

2.3 Liquidity

NTRA has a Current Ratio of 3.27. This indicates that NTRA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.27, NTRA is doing worse than 61.33% of the companies in the same industry.
A Quick Ratio of 3.13 indicates that NTRA has no problem at all paying its short term obligations.
NTRA's Quick ratio of 3.13 is on the low side compared to the rest of the industry. NTRA is outperformed by 60.19% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.27
Quick Ratio	3.13

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NTRA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.11%.
NTRA shows a strong growth in Revenue. In the last year, the Revenue has grown by 38.17%.
Measured over the past years, NTRA shows a very strong growth in Revenue. The Revenue has been growing by 41.20% on average per year.

EPS 1Y (TTM)-30.11%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-146.15%

Revenue 1Y (TTM)38.17%

Revenue growth 3Y39.47%

Revenue growth 5Y41.2%

Sales Q2Q%34.66%

3.2 Future

Based on estimates for the next years, NTRA will show a very strong growth in Earnings Per Share. The EPS will grow by 31.37% on average per year.
The Revenue is expected to grow by 20.48% on average over the next years. This is a very strong growth

EPS Next Y-60.42%

EPS Next 2Y-12.26%

EPS Next 3Y22.93%

EPS Next 5Y31.37%

Revenue Next Year34.32%

Revenue Next 2Y25.32%

Revenue Next 3Y23.03%

Revenue Next 5Y20.48%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

NTRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NTRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of NTRA indicates a rather cheap valuation: NTRA is cheaper than 90.48% of the companies listed in the same industry.